Long-term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus

Background & Aims We investigated the long-term efficacy and renal safety of tenofovir disoproxil fumarate (TDF), administered to patients co-infected with human immunodeficiency virus and hepatitis B virus (HBV) as part of an antiretroviral therapy. Methods We performed a multicenter, prospecti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 2010-12, Vol.139 (6), p.1934-1941
Hauptverfasser:	de Vries–Sluijs, Theodora E.M.S, Reijnders, Jurriën G.P, Hansen, Bettina E, Zaaijer, Hans L, Prins, Jan M, Pas, Suzan D, Schutten, Martin, Hoepelman, Andy I.M, Richter, Clemens, Mulder, Jan W, de Man, Rob A, Janssen, Harry L.A, van der Ende, Marchina E
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine - administration & dosage Adenine - adverse effects Adenine - analogs & derivatives Adult Anti-HIV Agents - administration & dosage Anti-HIV Agents - adverse effects Antiviral Agents - administration & dosage CD4 Lymphocyte Count DNA, Viral - blood Drug Resistance, Viral Entecavir Female Follow-Up Studies Gastroenterology and Hepatology Guanine - administration & dosage Guanine - analogs & derivatives Hepatitis B virus - drug effects Hepatitis B virus - genetics Hepatitis B virus - growth & development Hepatitis B, Chronic - complications Hepatitis B, Chronic - drug therapy Highly Active Antiretroviral Therapy HIV Infections - complications HIV Infections - drug therapy Humans Kaplan-Meier Estimate Kidney - drug effects Liver Disease Male Middle Aged Nephrotoxicity Organophosphonates - administration & dosage Organophosphonates - adverse effects Prospective Studies Tenofovir Time Factors Virus Replication - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background & Aims We investigated the long-term efficacy and renal safety of tenofovir disoproxil fumarate (TDF), administered to patients co-infected with human immunodeficiency virus and hepatitis B virus (HBV) as part of an antiretroviral therapy. Methods We performed a multicenter, prospective cohort study of 102 patients co-infected with human immunodeficiency virus and HBV who were treated with TDF. Results At baseline, 80% of patients had a detectable viral load (HBV DNA >20 IU/mL). Among patients positive for hepatitis B e antigen (HBeAg) (n = 67), 92% had a virologic response (HBV DNA
ISSN:	0016-5085 1528-0012
DOI:	10.1053/j.gastro.2010.08.045